Developed to facilitate a better understanding across the prevention field of needed near-term next steps and long-term future directions to fully realize
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
To celebrate Native American Heritage Month, we spoke with Karina Walters, Ph.D., M.S.W., Director of the NIH Tribal Research Health Office (THRO). Dr. Walters, an…
Explore the program for the AACR Special Conference in Cancer Research: Translating Targeted Therapies in Combination with Radiotherapy.
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Fully 1,600 cancer treatments and vaccines are in development, according to speakers at an AMCP Nexus 2024 presentation, in Las Vegas.
In this issue of Blood, Hu and colleagues show that reduced Yes-associated protein 1 (YAP1) expression in megakaryocytes (MK), via an impaired interaction
Key PointsOutcomes with single-agent gilteritinib across 38 National Health Service hospitals mirror those seen in clinical trials.Patients with adverse ka
Annual Meeting 2024 AACR Journals Concurrent Publications | American Association for Cancer Research AACR Annual Meeting 2024: AACR Journals’ Concurrent Publications The AACR journal articles…
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. An analysis of treatment-naïve patients with acute myeloid leukemia (AML)…
To be presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting, a phase II study by Riess et al investigating the IO102-IO103 vaccine…
